{"name":"Alto Neuroscience","slug":"alto-neuroscience","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxOMmQ1R2U0Z3dxcURyZHdHMUxUMldKR2NwdFNENi1sUTQwQnZMTHF2NWdGaFhvaXA2cEMtM2VSVmppN21NWUdQR2U1M1JfUktfQVBLbkEwcTlzZC1vZ2tZOTBncll6alZJTzJZWjhHeEIwTThLX0c5TXY0OGw5MlNqbTVGSXp5UkRpbHFPVE5WRFFRYWJUdU5TYU5udWdqUjBmRkxsb29vWVVXNzBpVmtEZGk3eTlld05XTnlqYWk0NmFIXzl5b19vM29BNEg0cnRzOEN4dmk5dw?oc=5","date":"2026-04-03","type":"regulatory","source":"The Globe and Mail","summary":"Chardan Capital Remains a Buy on Alto Neuroscience, Inc. (ANRO) - The Globe and Mail","headline":"Chardan Capital Remains a Buy on Alto Neuroscience, Inc. (ANRO)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE00R2dOZUd3UGxNRERwbGk4cTI1aGQ4VC01VlVieXhpTmRRQmQ4dmxFMGRfZEZIUXpWYWdtTXhtbHM5enkzb2tnZ2Y2dkdTd2VQZWRwaWVBNTZwb2NaaVHSAWNBVV95cUxQbnF1cUVpX2lUdEVkaHlibjNwa01ISkVhV0NyYk56RUdDaGpnSGpsaGdHWTBoNGdmZjNwTnFRZHV6RndjdzFsU1ZuLUxRYllGeThpMjlCMkYzUEdseDhVZlRGLUk?oc=5","date":"2026-04-03","type":"pipeline","source":"Bitget","summary":"Alto Rises 0.98% Amid Neutral Signals and Tariff Jitters - Bitget","headline":"Alto Rises 0.98% Amid Neutral Signals and Tariff Jitters","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAJBVV95cUxQZGZhUldiU3piWjBKcmRIOW9HbUtuUGJkdXJ6RmhtaDFEOTZHY2RQaDM2Y2hmSDcyRGZCWkgwSGN0RDIxYm0xTVRjMUVVX2cxTVdsRTQ0X1lGRGhha2k2Q0xHOFdPRFFxSm5zVnc1SnpPRmFDVUtrUFBhcHBTSE5HWlV1Vm5wMnpiY0swVDhsZjRIUzU0WXJjemRiUzJ6bUFnTVk3YXVhdWRsX01PM0d3dkE5aEdrX3NCTmFHeU43TnpIbEpFT09iejdadHY1ZnJ4d1ZpMnJjRXJ1NHh1U0ZmdkFDcHVyVFNXelRiVG9BVkRjOG9Qdzkya2JvMk9sWGFndFdXMlNncXhWSHJDTUFNUGN1OWZFZ1pYazBlVUd1QzJzWDJOWGFZOUhmWlNrVnJjbG9kRE9UOXhWalMz?oc=5","date":"2026-03-11","type":"pipeline","source":"PR Newswire","summary":"Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancements in Psychiatric Therapies | DelveInsight - PR Newswire","headline":"Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancem","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQV2pPbUxBY2VENGhsbFY0QnEtWTVIaS1SNG91WTJ0cTVvMjJUNHNRNVBEaEZBOFdWYkZ5N2NZTWI4LTZoejNlTXl0dVdUWU5WYThucjFDeVJORFRxUE1MRUE3dGZTNU85bWtwMnBOVFhpSUhLV1pfODRaVXIzYTlTM3RUenAzdw?oc=5","date":"2026-03-11","type":"pipeline","source":"Crunchbase","summary":"Spruce Street Capital - Financial Details - Crunchbase","headline":"Spruce Street Capital - Financial Details","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE9pUVdjc2hCUTYxckp5ZVI4U0xqVUR1RTBBeFVXdUo4VUR1SVI4MnZNY3VhQWEyMFltekJkd1d4UmpOc0kxdW9CTnpkRHE2Z0FvZlVyN2lzZVpVaXcwblJOMVlEclFianFUcnhLRjluTzZSZw?oc=5","date":"2026-01-13","type":"pipeline","source":"pharmaphorum","summary":"Is this the year for precision psychology? With Amit Etkin - pharmaphorum","headline":"Is this the year for precision psychology? With Amit Etkin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPck83aTdEaXhTcmQ1WkJuMTNRTXItLXVjY0s5dEhVODI1V3BvLVZqMGlZVHd0dll4Q3RiWU9yc0hkOVZ6dGRNems5WU9TSUxST0szaHR6MXJvSDAtX09ISTNfYmF3RXhMek1zeWtWNE9pcG1tODB0aUFYVjl1T2sta19Xa0w0aUlQS1FPR3dfRUMxLW9xVlNuSFlxU1V1R2V0Z1FTSnhaSVJpSVFwNVE?oc=5","date":"2025-10-21","type":"pipeline","source":"The Pharma Letter","summary":"Alto Neuroscience rockets on news of $50 million private placement - The Pharma Letter","headline":"Alto Neuroscience rockets on news of $50 million private placement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNVjdXdHh1RkloUmMxRE9Bam1jME15c2dEYTBMeXpNWHU5OWhJd0NsUVdzOVZCdDNob2kwV3lxR3lXSFZRUHlWZXB4UGp4QVVnRUlFRzhCRzFpcnVQU3RjcUM5dTBEaF9vTkZjaUZ2bXhCVjR1bUxZOV9mTmYzZGtBUlhvUzIxVFhlZUxNUjQ0YzVUV211MHEzaWQwTmI?oc=5","date":"2025-10-20","type":"pipeline","source":"BioPharma Dive","summary":"Alto shares double on plans to speed depression drug’s development - BioPharma Dive","headline":"Alto shares double on plans to speed depression drug’s development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQMXF6V1k2VEVZaTd6Mzd1WWZxSGNJR2lhckJrR3J5aUhSUTlxbjU1N083YV9XTjRmS193empuYkRXWEdBS3VXa1dNcDM3Q25fYlh5VjU4N2tGQmx5Ymx1cnRycWF2WjdpU2NjZFNwcVg5SFRpbTB6aURSeXk1ZWJVN0tFRkZ0Tk5UaTJhY0phZUZtcFpKWXMtNUk3ZzBkVU1wTVR2cUJoVkdGUDZYTFpUUzk2Z3BTU09TVXZpeVRsVQ?oc=5","date":"2025-10-20","type":"trial","source":"Stock Titan","summary":"$50M financing enables Alto Neuroscience to accelerate ALTO-207 — Phase 2b 2026; Phase 3 early 2027 - Stock Titan","headline":"$50M financing enables Alto Neuroscience to accelerate ALTO-207 — Phase 2b 2026; Phase 3 early 2027","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-05","type":"regulatory","source":"simplywall.st","summary":"Alto Neuroscience: Evaluating Valuation After FDA Fast Track Win for ALTO-101 - simplywall.st","headline":"Alto Neuroscience: Evaluating Valuation After FDA Fast Track Win for ALTO-101","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQVmdtSjZWVDRGMzhBS3VsdFJMX3d6Rmlwb05vdS1qVWZnMlJXR0xCc3FnUC14dG5UQWVDUDVfWVl1Z01rbjZUR3RrRWpkblhyeC1LLU5kNS0tTXNmZ0JGQ0RLUk1BNUNaNzU1aTlWNDdXdXpQN040OHl0WGFjWGRkQjQ1Q0NNcDBKblNoamZVTHYydEkyMVViQ0g2MHZDdDhsYV9NRE5Jc21nOWJ6S3Riam15TS0xbVJCa3JjTEREdlo?oc=5","date":"2025-10-03","type":"regulatory","source":"Contract Pharma","summary":"Alto Neuroscience’s Schizophrenia Treatment Granted FDA Fast Track Designation - Contract Pharma","headline":"Alto Neuroscience’s Schizophrenia Treatment Granted FDA Fast Track Designation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPR2JfMlo2LUthMFFESW0zOE5LWERZUTZqNmpJd2prcm9rV0FYVEliWjVXY1ZLUXhZTTg5RmF0SmxWbXVhSTgtbTRFY2VQLThsS3ltZ3pyenl0T3pJaGhma1ZoWGRFaUVYZDRnYjNqTzhyWnlKWDExY0puM2JMemdOdmUzdDBaVzlzQ1B0ZDhVNTVBcEJsM2JEYktSR2EwbVZVSVdTMExIdFF2QzlkSlRVX0gtRE9MNFdBT1diNWhKd3A3blpUOHpISnFWYldjckE5T2NQcXlDSkNIc2NjNlhnWm9Kd0ZVck4tanZQZVNPRXFJZDU0a3VHN1gzVlVnLVc4Q1YzRzVNb3g?oc=5","date":"2025-09-11","type":"pipeline","source":"globenewswire.com","summary":"Bipolar Disorder Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight - globenewswire.com","headline":"Bipolar Disorder Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9wbHkzV3dGRHNlUDFaUUxYYnN6dG1tcGRkNi1oanEyR0JFeHAwaUlmSDNKNXdUcE0zMWdPNFBPc1N0Wm5ITGo5YlluVlV4MkloT2pr?oc=5","date":"2025-06-03","type":"trial","source":"FirstWord Pharma","summary":"Alto adds resistant depression asset following drug trial flop - FirstWord Pharma","headline":"Alto adds resistant depression asset following drug trial flop","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}